Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

@article{Oxnard2013NaturalHA,
  title={Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.},
  author={Geoffrey R. Oxnard and Peter Lo and Mizuki Nishino and Suzanne E Dahlberg and Neal I Lindeman and Mohit Butaney and David Michael Jackman and Bruce Evan Johnson and Pasi Antero J{\"a}nne},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2013},
  volume={8 2},
  pages={179-84}
}
INTRODUCTION Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. METHODS NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 8 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 4 Excerpts
Highly Influenced

Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 2 Excerpts

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 4 Excerpts

Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2012
View 1 Excerpt

Improved survival with MEK inhibition in BRAF-mutated melanoma.

The New England journal of medicine • 2012
View 1 Excerpt

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced nonsmall cell lung cancer (NSCLC)

EB Garon, T Moran, F Barlesi
ASCO Meeting Abstracts • 2012

ROS1 rearrangements define a unique molecular class of lung cancers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…